Psychedelics and antidepressants: a new study lowers expectations, but does not close the door to new therapies
A new meta-analysis published on March 18, 2026, in the journal
JAMA Psychiatry reaches a conclusion that could change the tone of the public debate on psychedelic therapy for depression. According to that analysis, psychedelics such as psilocybin and LSD in the treatment of major depressive disorder did not show a better effect than classic antidepressants when the comparison is set up so that both types of therapy are under an equal influence of patient expectations. This does not mean that psychedelics are ineffective, nor that interest in their use has disappeared overnight. It does mean, however, that part of the enthusiasm so far may not have stemmed only from the pharmacological action of these substances, but also from the way individual trials were designed. It is precisely this methodological problem that the study authors place at the center of the discussion, arguing that without resolving it, it is not possible to fairly assess how much psychedelics are truly superior and how much they have simply been studied differently.
The question is important because depression continues to rank among the greatest public health challenges. The World Health Organization estimates that depression is experienced by about 4 percent of the world’s population, that is, approximately 332 million people, and the illness can seriously impair everyday functioning, relationships, work capacity, and general health. WHO also emphasizes that there are effective forms of treatment for depression, including psychological therapies and medications, and that the choice of approach depends on the severity of symptoms, the availability of care, and the individual circumstances of the patient. In such a context, every announcement of a “revolutionary” treatment understandably attracts great attention, especially when it concerns patients for whom standard therapy does not bring sufficient relief. That is precisely why the new study is drawing interest far beyond the narrow circle of psychiatry researchers.
What the new study actually compared
The authors of the paper did not conduct one new clinical trial, but rather performed a systematic review and meta-analysis of the available research. They included 24 studies in the analysis that met pre-set criteria. Among them were eight trials of psychedelic-assisted therapy with a total of 249 patients, and 16 open-label trials of traditional antidepressants with a total of 7,921 patients. The main question was simple, but methodologically demanding: how does psychedelic therapy perform relative to antidepressants when studies are compared in which participants know that they are receiving active treatment?
This may seem like a technical detail, but in this field it is crucial. In classic double-blind trials, neither the patient nor the researcher knows who receives the drug and who receives the placebo. Such an approach serves to reduce as much as possible the effect of expectations, hope, disappointment, and other psychological factors that may influence reported symptoms. With psychedelics, that model, at least for now, is very difficult to maintain. Substances such as LSD or psilocybin produce strong and recognizable subjective effects, which is why many participants quickly realize whether they received the active substance or a placebo. When that happens, the study’s “blindness” practically disappears.
The authors of the paper argue that this is precisely where a major methodological asymmetry arises between psychedelic and standard antidepressant research. In psychedelic studies, participants in the placebo group often conclude that they did not receive active treatment, so their expectations may drop, and with them their reported sense of improvement. In antidepressant research, on the other hand, the line between the active drug and placebo is more often less clear to the patient, so placebo groups not infrequently show greater progress than in psychedelic trials. If results obtained under such different conditions are then compared, psychedelics may appear more powerful than they would in a comparison of methodologically equalized conditions.
Result: the advantage of psychedelics disappeared when the conditions were equalized
According to the summary published in
JAMA Psychiatry, the meta-analysis did not show a statistically significant difference in patient improvement after psychedelic-assisted therapy and openly administered traditional antidepressants. The estimated difference was 0.3 points in favor of openly administered antidepressants, with a confidence interval that did not indicate a clear advantage for either approach. In other words, when psychedelics are not compared with classic placebo-controlled antidepressant trials, but with trials in which patients on antidepressants also know that they are receiving an active drug, the large advantage of psychedelics is no longer visible.
In a press release from the University of California, San Francisco, where some of the authors are based, it is stated that patients in both types of trials improved their score on the standard depression symptom scale by about 12 points on average. The researchers openly acknowledged that the outcome surprised them. Clinical data scientist Balázs Szigeti from UCSF’s Translational Psychedelic Research Program said that he himself had expected psychedelics to retain a clear advantage even when compared with open-label antidepressant trials, but the analysis showed the opposite. His message is not that psychedelics have no place in therapy, but that their real benefits can only be assessed when the comparison is set up fairly.
One of the additional findings of the paper points in the same direction. The authors state that open-label trials of traditional antidepressants were associated with somewhat better outcomes than blind trials of the same drugs, suggesting that expectations also play a role there. With psychedelics, however, the same difference was not clearly observed, which the authors interpret as confirmation that such trials are in practice almost always functionally open, even when they are formally designed as blind. That is perhaps the most important message of the entire paper: the debate is no longer only about whether psychedelics work, but also about how to measure their effect at all without the methodological advantage provided by a recognizable subjective experience.
Why the problem of “unblinding” is so important
In public, psychedelic therapy has in recent years often been presented as a potential breakthrough in the treatment of depression, especially because of the impression that it may act faster and more powerfully than standard medications. That impression did not arise without reason. Several earlier studies did indeed show very promising results, especially in patients with more difficult-to-treat forms of depression. But some experts had already been warning for a longer time that this field is particularly sensitive to the so-called expectancy effect, that is, the influence of expectations on the outcome.
With psychedelics, that effect is difficult to ignore because the experience of taking the drug is not subtle. A participant who, after a dose, experiences strong changes in perception, emotions, or the sense of time and space generally has no doubt whether they received an active substance. The same similarly applies to therapists or researchers observing such a state. This erases one of the fundamental mechanisms by which medical research tries to separate the pharmacological effect of a drug from the psychological effect of expectation. The new study does not claim that the entire effect of psychedelics is “just placebo,” but it does claim that without solving this problem, it is very easy to overestimate how large the real difference is compared with existing therapies.
Such a conclusion is especially important at a time when significant funds are being invested around the world into the development of psychedelic therapies, regulatory discussions, and new clinical protocols. The U.S. Food and Drug Administration, FDA, had already previously published draft guidance for clinical trials of psychedelic drugs, emphasizing that this is an area requiring special attention in terms of safety, study design, and interpretation of results. This shows that the regulatory system is not rejecting research, but is also viewing it with increased caution. The new meta-analysis therefore will not necessarily slow the entire field, but it could strengthen demands for stricter methodology and more moderate public expectations.
What this study does not say
It is equally important to understand what the new analysis does not claim. It does not show that psychedelics do not work for depression. Nor does it show that they are worse than antidepressants. The conclusion is narrower and more precise: when the effect is compared under conditions that equalize the influence of expectations, psychedelic-assisted therapy did not show a better result than openly administered traditional antidepressants. That is a big difference from claiming that it is a therapy without value.
Moreover, “psychedelic therapy” is not an unambiguous term. Different studies use different substances, doses, therapeutic frameworks, numbers of sessions, inclusion criteria, and measurement tools. In some trials, the emphasis is placed on the pharmacological effect, and in others on the comprehensive model that includes preparation, guided experience, and integration conversations after the session. Traditional antidepressants also constitute a heterogeneous group of drugs, with different profiles of efficacy and side effects. A meta-analysis can show a general direction, but it cannot fully resolve the question of which approach works better for which patients, under which circumstances, and under which protocols.
It should also be kept in mind that part of the interest in psychedelics stems from the hypothesis of faster action in some patients and the possibility that the therapeutic effect does not depend only on daily intake of the drug. The new analysis speaks about the overall improvement of depression symptoms, but by itself it does not close questions of duration of effect, patient subgroups, tolerability, side effects, the logistical demands of therapy, and implementation costs. In other words, the study is an important correction to the narrative, but it is not a final verdict on the entire field.
The broader context of depression treatment
Both official clinical guidelines and international public health institutions have for years emphasized that depression does not have one universal solution. WHO states that psychological therapies are the first choice of treatment for many people with depression and that in moderate and severe forms they are often combined with medication. In its guidelines for adults, the American Psychological Association recommends several psychotherapeutic approaches, but also second-generation antidepressants as one of the standard treatment options. In practice, this means that depression is treated with a combination of different tools, not by a simple search for one “miracle” solution.
That is why the message of the new study, although it sounds cold compared with earlier enthusiasm, is actually useful for the public and the healthcare system. It is a reminder that a new therapy does not automatically become better just because it is new, media-attractive, or associated with a dramatic experience. In the field of mental health, it is especially important to distinguish hope from evidence. Patients with severe depression, their families, and doctors have the right to expect that new solutions will be assessed strictly, equally, and without embellishment.
This is all the more true because depression often affects people in very vulnerable phases of life. According to WHO, the illness can seriously impair functioning at home, at work, and in the community, and is also associated with an increased risk of suicide. In such circumstances, overly simplified messages about a “turning point” or a “miracle” can be dangerous because they encourage unrealistic expectations. On the other hand, it would be equally wrong to draw from the new meta-analysis the conclusion that psychedelics should be discarded. A reasonable interpretation would be that the field is maturing and is now entering a phase in which it will have to offer stronger evidence, define more precisely for whom the therapy makes sense, and show whether it can keep its promise even under stricter research conditions.
Will this publication change the direction of research
Very likely yes, but more in the sense of methodological tightening than a complete reversal. The very fact that the paper was published in a respected medical journal and comes from a circle of researchers who did not take a hostile stance toward psychedelics in advance gives it additional weight. When authors who themselves expected a better result for psychedelics publish that they did not find it, that resonates differently than when doubt is expressed by outside critics. In that sense, this study probably will not stifle research, but it could influence how control groups are set up in the future, how participant expectations are measured, and how preliminary results are presented to the public.
For advocates of psychedelic therapy, this is an uncomfortable, but not necessarily devastating moment. If it turns out that certain substances or therapeutic protocols do in fact offer special advantages, they will have to be demonstrated in study designs that neutralize the expectancy effect as much as possible. If that does not turn out to be the case, then psychedelics may remain one of the possible options within the broader treatment arsenal, but without the status of a superior solution. In both cases, the gain should be greater scientific clarity.
For patients and the broader public, perhaps the most down-to-earth message is the most important: depression remains a serious, common, and treatable illness, but no single piece of news should be read as a final answer. The new research published on March 18, 2026, does not overturn the whole idea of psychedelic therapy, but it clearly states that current evidence does not support the claim that psychedelics are better than antidepressants when both therapies are observed under comparable conditions. After years of very high expectations, precisely that more sober assessment may be the most valuable contribution to the debate on how to truly improve the treatment of depression.
Sources:- - JAMA Psychiatry – summary of the systematic review and meta-analysis on the comparison of psychedelic-assisted therapy and openly administered antidepressants for the treatment of depression (link)
- - University of California, San Francisco – press release on the study, with statements from the authors and an explanation of the “blinding” problem in psychedelic research (link)
- - World Health Organization – overview of the prevalence of depression and the basic principles of diagnosis and treatment (link)
- - American Psychological Association – guidelines for the treatment of depression in adults, including psychotherapy and antidepressants as standard options (link)
- - U.S. Food and Drug Administration – draft guidance for clinical trials of psychedelic drugs, as the regulatory context for the development of this field (link)
Find accommodation nearby
Creation time: 4 hours ago